Sex and the (Not Quite) Single Arthritis Patient
(MedPage Today) -- COPENHAGEN -- Half of patients with rheumatoid arthritis (RA) and 30% of those with psoriatic arthritis (PsA) reported substantial problems with sexual function, according to a survey reported here.
Among 27 with RA diagnoses... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - June 2, 2022 Category: OBGYN Source Type: news
New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Lance Bass' Psoriatic Arthritis
(MedPage Today) -- Former 'NSYNC member Lance Bass recently revealed that he has been living with psoriatic arthritis for the past 5 years. In an interview with People magazine, Bass said: "I had symptoms before, but you know, I kind of just dealt... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 27, 2022 Category: Dermatology Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and inno...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Episode 6: Emerging and Novel Therapeutics in the Management of PsA Episode 6: Emerging and Novel Therapeutics in the Management of PsA
Elaine Husni, MD, MPH, and Ana-Maria Orbai, MD, MHS, discuss the emerging and novel therapeutics in psoriatic arthritis and the impact that they will have on their patients.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 18, 2022 Category: Consumer Health News Tags: Rheumatology InDiscussion Source Type: news
Hypocaloric Diet Controls Joint Activity in Psoriatic Arthritis Hypocaloric Diet Controls Joint Activity in Psoriatic Arthritis
A 12-week hypocaloric diet provided suitable control of joint disease activity in patients with psoriatic arthritis, regardless of weight loss, Brazilian researchers found.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 15, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
Response Time for Outcomes in Psoriatic Arthritis Treatment Response Time for Outcomes in Psoriatic Arthritis Treatment
When can a meaningful response be expected with psoriatic arthritis treatments? A better understanding could help guide treatment decisions.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
What Are the Main Causes of Psoriatic Arthritis?
Title: What Are the Main Causes of Psoriatic Arthritis?Category: Diseases and ConditionsCreated: 3/29/2022 12:00:00 AMLast Editorial Review: 3/29/2022 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 29, 2022 Category: Rheumatology Source Type: news
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA ® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials.1 A separate post hoc analysis of the VOYAGE studies showed TREMFYA provided high rates of efficacy and durability through five years and similar safety outcomes among patients with and without...
Source: Johnson and Johnson - March 25, 2022 Category: Pharmaceuticals Source Type: news
Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis
HORSHAM, PENNSYLVANIA, March 22, 2022 – Psoriasis (PsO) can take a physical, psychological, and emotional toll on the more than 8 million Americans living with the disease; and for people of color, there are additional challenges due to limited medical research and education, as well as underrepresentation in clinical studies.1,2,3 This has led to a lack of data and barriers to optimal care for diverse patient populations.2 PsO may also present with less noticeable skin reddening on darker skin tones, which can make it harder for healthcare providers to identify and lead to misdiagnoses in people of color. To help addres...
Source: Johnson and Johnson - March 23, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Gauging Cardiovascular Risk in Psoriatic Disease: It's Complicated
(MedPage Today) -- Clinicians treating patients with psoriasis or psoriatic arthritis should know that certain biomarkers of cardiovascular risk may provide extra information beyond what's included in conventional prediction tools, researchers... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - March 9, 2022 Category: Rheumatology Source Type: news
Methotrexate Plus Leflunomide Proves Effective for PsA Methotrexate Plus Leflunomide Proves Effective for PsA
The combination therapy outperformed methotrexate monotherapy as a treatment option for patients with psoriatic arthritis (PsA), though it did come with an increase in side effects.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 8, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
Rheumatoid Arthritis vs. Psoriatic Arthritis
Title: Rheumatoid Arthritis vs. Psoriatic ArthritisCategory: Diseases and ConditionsCreated: 3/4/2022 12:00:00 AMLast Editorial Review: 3/4/2022 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 4, 2022 Category: Rheumatology Source Type: news
